🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Oxford
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Oxford

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2846 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 20 Sep 2026, 03:15 UTC
2846
Studies in scope
industry-sponsored, all four open statuses
1377
Recruiting now
open to new participants
539
Lead sponsors
across recruiting studies
Top sites
London 2003 Manchester 674 Birmingham 469 Glasgow 437 Cambridge 416
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca20 AbbVie17 Hoffmann-La Roche16 Eli Lilly and Company15 Merck Sharp & Dohme LLC14
Site city
London2003 Manchester674 Birmingham469 Glasgow437 Cambridge416
All 426 cities
Target enrolment
to
363 of 2846 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Active, closed
A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors
NCT05614102Advanced Solid Tumors
Bayer
Phase 1
284
London, Oxford, Sutton, Newcastle upon Tyne
2022-11-04
Active, closed
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
NCT05169515Non-Hodgkin Lymphoma
Hoffmann-La Roche
Phase 1
121
Glasgow, London, Nottingham, Oxford
2022-10-26
Active, closed
A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp
NCT05387525Keratosis, Actinic
Almirall, S.A.
Phase 4
447
London, Oxford, Poole, Weston-super-Mare
2022-10-24
Recruiting
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
NCT05372354Multiple Myeloma
Bristol-Myers Squibb
Phase 1/2
260
Manchester, Leicester, Liverpool, Oxford, London
2022-10-18
Active, closed
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
NCT05371093Relapsed/Refractory Follicular Lymphoma
Kite, A Gilead Company
Phase 3
231
Birmingham, Cambridge, London, Manchester, Oxford, Southampton, Sutton
2022-09-22
Active, closed
The Euro-CRAFT Registry
NCT05805462Coronary Microvascular Disease
CoreAalst BV
Observational
671
Bath, Bristol, Essex, Glasgow, London, Oxford
2022-09-22
Active, closed
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
NCT05409066Follicular Lymphoma (FL)
Genmab
Phase 3
549
Plymouth, Glasgow, London, Oxford, Leeds, Birmingham, Colchester, Liverpool
2022-09-20
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05242484Colitis, Ulcerative
Janssen Research & Development, LLC
Phase 2
577
Belfast, Cambridge, Glasgow, High Wycombe, London, Oxford
2022-09-19
Active, closed
Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis
NCT05570058IPF, Fibrosis
Redx Pharma Ltd
Phase 2
48
Belfast, Birmingham, Cambridge, Edinburgh, London, Londonderry, Oxford
2022-09-08
Recruiting
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
NCT05533697Advanced Solid Tumors
ModernaTX, Inc.
Phase 1/2
361
Preston, Glasgow, Birmingham, London, Manchester, Oxford, Southampton
2022-09-01
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Novartis Pharmaceuticals
Phase 4
347
London, Oxford
2022-08-30
Active, closed
A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
NCT05399888Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
Biogen
Phase 2
416
London, Manchester, Southampton, Oxford, Sheffield, Motherwell, Birmingham, Bristol
2022-08-24
Active, closed
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
NCT05536973Neovascular Age-related Macular Degeneration
Adverum Biotechnologies, Inc.
Phase 2
69
London, Oxford
2022-08-23
By invitation
Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
NCT05374590Generalized Myasthenia Gravis, gMG
argenx
Phase 2/3
12
London, Oxford
2022-08-18
Active, closed
An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice
NCT05494606Ulcerative Colitis
AbbVie
Observational
785
Exeter, Hull, Basingstoke, Bury, Kettering, Nottingham, Oxford, Belfast
2022-08-15
Recruiting
A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
NCT05463263Lymphoma, B-Cell, Lymphoma, T-Cell
Step Pharma, SAS
Phase 1/2
180
Leicester, London, Manchester, Nottingham, Oxford, Plymouth, Sutton
2022-08-03
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471Crohn's Disease
Janssen Research & Development, LLC
Phase 2
703
Belfast, Birmingham, Cambridge, Glasgow, High Wycombe, London, Oxford, Wolverhampton
2022-07-22
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
Merck Sharp & Dohme LLC
Phase 2
189
Truro, London, Oxford, Manchester
2022-07-21
Recruiting
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)
NCT04165486Multiple System Atrophy
Ionis Pharmaceuticals, Inc.
Phase 1
40
London, Oxford, Salford, Southampton
2022-07-21
Recruiting
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
NCT05413850Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC, Urogenital Neoplasms
Blue Earth Therapeutics Ltd
Phase 1/2
82
Bristol, Glasgow, London, Middlesbrough, Oxford, Sheffield, Southampton
2022-07-20
Active, closed
A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy
NCT05337553Spinal Muscular Atrophy, Neuromuscular Diseases, SMA
Biohaven Pharmaceuticals, Inc.
Phase 3
269
Glasgow, Oxford
2022-07-06
Active, closed
Merit WRAPSODY™ Endoprosthesis for Treatment of Stenosis or Occlusion (WRAP)
NCT05062291Venous Stenosis, Venous Occlusion
Merit Medical Systems, Inc.
Observational
500
Belfast, Birmingham, London, Oxford, Reading
2022-06-23
Active, closed
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04975997Multiple Myeloma
Celgene
Phase 3
939
Nottingham, Belfast Northern Ireland, Birmingham, Canterbury Kent, Lancashire Blackpool, London, Oxford, Portsmouth
2022-06-23
Recruiting
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
NCT05462106Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease
AC Immune SA
Phase 1/2
304
Cambridge, Liverpool, London, Oxford, Warrington
2022-06-21
Active, closed
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
NCT04970901B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
ADC Therapeutics S.A.
Phase 1
154
London, Oxford
2022-06-17
Rows per page Showing 226–250 of 363
Previous 8 9 10 11 12 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-uk/city/oxford

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.